secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001171843-26-001526
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M
--------------------------------------------------------------------------------

- Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).
- Cash $56.8M at Dec 31, 2025; $189.4M net from Jan 2026 offering extends runway into Q2 2028.
- Cohort 4 atopic dermatitis: 75% soquelitinib patients achieved EASI 75 vs 20% placebo; 33% IGA 0/1 vs 0%.
- Initiated Phase 2 atopic dermatitis trial in Q1 2026; ~200 patients, four dose arms, 12-week treatment.
- Phase 3 PTCL registrational trial enrolling; soquelitinib granted Fast Track and Orphan Drug Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/0001171843-26-001526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/f8k_031226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer